Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

Recent developments and future perspectives in the systemic treatment of metastatic colorectal... Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal growth factor receptor (EGFR)-antibodies is now routinely implemented in clinical practice to define the subgroup of patients benefiting most from treatment. This review discusses the current status of treatment strategies using intermittent and maintenance therapy concepts based on recent clinical trials. Furthermore, the conflicting data on the use of the monoclonal EGFR-antibody cetuximab in combination with oxaliplatin containing chemotherapy derived from recent phase III trials are summarised and discussed. Finally, first clinical data on the use of monoclonal antibodies against novel targets (i.e. Hepatocyte Growth Factor and Insulin-like Growth Factor-1 Receptor) are presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

Loading next page...
 
/lp/springer-journals/recent-developments-and-future-perspectives-in-the-systemic-treatment-2e4t0lR93T
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0265-4
Publisher site
See Article on Publisher Site

Abstract

Systemic treatment of metastatic colorectal cancer is increasingly being tailored towards the individual clinical situation of the patient. In particular, the k-ras mutation status as a predictive marker for the therapeutic efficacy of epidermal growth factor receptor (EGFR)-antibodies is now routinely implemented in clinical practice to define the subgroup of patients benefiting most from treatment. This review discusses the current status of treatment strategies using intermittent and maintenance therapy concepts based on recent clinical trials. Furthermore, the conflicting data on the use of the monoclonal EGFR-antibody cetuximab in combination with oxaliplatin containing chemotherapy derived from recent phase III trials are summarised and discussed. Finally, first clinical data on the use of monoclonal antibodies against novel targets (i.e. Hepatocyte Growth Factor and Insulin-like Growth Factor-1 Receptor) are presented.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 30, 2011

References